Summit Therapeutics Announces Updated Phase III OS Results for Ivonescimab

What Happened

• On July 22, 2026, Summit Therapeutics (SMMT) filed an 8-K and issued a press release announcing updated overall survival (OS) results from the Phase III HARMONi trial of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with EGFR‑mutated, locally advanced or metastatic non-squamous non‑small cell lung cancer previously treated with a third‑generation EGFR tyrosine kinase inhibitor. The updated analysis used a data cutoff of June 2026.

Key Details

• Hazard ratio (HR) for overall survival: 0.76 for the full trial population (same 0.76 HR observed in western patient subgroups in this analysis).
• Median follow-up: western patients reached 23.2 months; Asian patients remained locked with median follow-up of 32.7 months from the primary analysis.
• Safety: ivonescimab plus chemotherapy continued to show an acceptable and manageable safety profile with no additional safety signals versus prior Phase III data.
• Regulatory/communication: the OS results have been provided to the FDA; more detailed data are planned for presentation at an upcoming medical conference.

Why It Matters

• Investors should note the reported HR of 0.76, which is a concrete measure from the trial analysis indicating a lower risk of death in the treatment arm during this follow‑up period. These updated OS data, the safety consistency, and the company’s communication to the FDA are material steps in the clinical and regulatory story for ivonescimab. Watch for the forthcoming conference presentation and any FDA feedback or regulatory filings for more detailed efficacy and safety information.